On September 3, 2019, Melinta Therapeutics, Inc. announced that its Board of Directors appointed Jennifer A. Sanfilippo, the Company's former Senior Vice President and General Counsel, as interim chief executive officer of the Company (CEO), effective August 28, 2019. The Board also appointed Ms. Sanfilippo to the Board as a Class III director, effective August 28, 2019. Ms. Sanfilippo succeeds John H. Johnson, who had been serving as acting chief executive officer of the Company since his resignation from his position as chief executive officer of the Company effective August 5, 2019.

Mr. Johnson also resigned from the Board and all committees of the Board effective August 5, 2019. Ms. Sanfilippo, age 40, has served as Senior Vice President and General Counsel of the Company since November 2018, responsible for both legal and compliance matters for the Company and brings substantial experience as a life sciences executive with a demonstrated record of achievement in these areas.